CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
11.86
+0.20 (1.72%)
At close: May 12, 2025, 4:00 PM
11.85
-0.01 (-0.08%)
After-hours: May 12, 2025, 7:14 PM EDT
Company Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedix Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Mar 25, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Joseph Todisco |
Contact Details
Address: 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 United States | |
| Phone | 908 517 9500 |
| Website | cormedix.com |
Stock Details
| Ticker Symbol | CRMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410098 |
| CUSIP Number | 21900C308 |
| ISIN Number | US21900C3088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph Todisco MBA | Chief Executive Officer and Director |
| Dr. Matthew T. David M.D. | Executive Vice President and Chief Financial Officer |
| Elizabeth Masson-Hurlburt B.A. | Executive Vice President and Chief Clinical Strategy and Operations Officer |
| Kaufman Beth Zelnick Esq. | EVice President, Chief Legal, Compliance Officer and Corporate Secretary |
| Donna Ucci | Senior Vice President and Head of Global Quality |
| Dr. Tushar Mukherjee | Senior Vice President and Head of Technical Operations |
| Erin Mistry | Executive Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 8, 2025 | 8-K | Current Report |
| Apr 4, 2025 | SCHEDULE 13G | Filing |
| Mar 25, 2025 | 10-K | Annual Report |